Squamous cell carcinoma of the oral cavity

5 trials 2 recruiting MedDRA PT
5 Registered trials
2 Recruiting
5 Unique sponsors
6 Unique IMPs
0 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
L Oncology (ATC L) 4
Mechanism of action (INN-stem analysis)
Kinase inhibitor 2 substances
Platinum compound 1 substance
Taxane 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Phase II: 4 Phase III/IV: 1

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase II

4 trials
  • Fondazione GONO Plus Academic
    CARBOPLATIN; PACLITAXEL; TISLELIZUMAB
    2024-517565-16-00 1 country n=28
    Pending
  • Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau Academic
    AFATINIB
    2024-511477-29-00 2 countries 2024 n=25 Orphan
    Recruiting
  • Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy Academic
    CARBOPLATIN; PACLITAXEL
    2024-517480-23-00 1 country 2022 n=40
    Recruiting
  • Universitaet Des Saarlandes Academic
    LENVATINIB; PEMBROLIZUMAB
    2024-516536-10-00 1 country 2023 n=50
    Ended

Phase III/IV

1 trial
  • Universitair Medisch Centrum Utrecht Academic
    IMP not specified
    2025-521682-27-00 1 country n=94
    Suspended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Universitair Medisch Centrum Utrecht Academic 1 Phase III/IV 0
Fondazione GONO Plus Academic 1 Phase II 0
Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau Academic 1 Phase II 1
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy Academic 1 Phase II 1
Universitaet Des Saarlandes Academic 1 Phase II 0
New trials by year
2022
1
2023
1
2024
1
← All indication landscapes